Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Dean Y Maeda"'
Autor:
Hanne Lind, Lucas A Horn, Jeffrey Riskin, Heidi A Hempel, Kristen K McCampbell, Dean Y Maeda, John A Zebala
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundDespite the success of immune checkpoint blockade therapy in the treatment of certain cancer types, only a small percentage of patients with solid malignancies achieve a durable response. Consequently, there is a need to develop novel appro
Externí odkaz:
https://doaj.org/article/13511483f12b409eb6e9c8522f26161d
Autor:
Vidya C. Sinha, Amanda L. Rinkenbaugh, Mingchu Xu, Xinhui Zhou, Xiaomei Zhang, Sabrina Jeter-Jones, Jiansu Shao, Yuan Qi, John A. Zebala, Dean Y. Maeda, Florencia McAllister, Helen Piwnica-Worms
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
The classification of breast lesions as indolent or aggressive to tailor treatment is crucial. Here, the authors use single-cell transcriptomics and multiparametric imaging of a breast cancer mouse model, report distinct tumor-immune features for the
Externí odkaz:
https://doaj.org/article/edf450673bba4946ad0410cdc2344397
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2020)
Tramadol is widely used globally and is the second most prescribed opioid in the United States. It treats moderate to severe pain but lethal opioid-induced respiratory depression is uncommon even in large overdose. It is unknown why tramadol spares r
Externí odkaz:
https://doaj.org/article/02111778d07a4ee8a972583f7ab1f827
Autor:
David A. Sallman, Amy E. DeZern, Arlene A. Gayle, Stuart J. Kahn, Eric Padron, Jeffrey E. Lancet, Andrew Kuykendall, Kendra Sweet, Onyee Chan, Dean Y. Maeda, Aaron D. Schuler, John A. Zebala, Rami S. Komrokji
Publikováno v:
Blood. 140:2070-2072
Autor:
Benjamin G. Neel, Kwok-Kin Wong, Aristotelis Tsirigos, Cynthia A. Loomis, Argus Athanas, Peter Olson, James G. Christensen, Dean Y. Maeda, John A. Zebala, Carmine Fedele, Yuan Hao, Ting Chen, Kayla Guidry, Han Han, Jayu Jen, Alireza Khodadadi-Jamayran, Shuai Li, Kwan Ho Tang
SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in normal cell signaling; hence, SHP2is could influence the tumor microenvironment. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ac5bb67a60ff5aa42b51919267a87ea
https://doi.org/10.1158/2159-8290.c.6549436.v1
https://doi.org/10.1158/2159-8290.c.6549436.v1
Autor:
Benjamin G. Neel, Kwok-Kin Wong, Aristotelis Tsirigos, Cynthia A. Loomis, Argus Athanas, Peter Olson, James G. Christensen, Dean Y. Maeda, John A. Zebala, Carmine Fedele, Yuan Hao, Ting Chen, Kayla Guidry, Han Han, Jayu Jen, Alireza Khodadadi-Jamayran, Shuai Li, Kwan Ho Tang
Table S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07fbd70898706deb6c68333d4b97a8f4
https://doi.org/10.1158/2159-8290.22540627
https://doi.org/10.1158/2159-8290.22540627
Figure S1-6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Autor:
Benjamin G. Neel, Kwok-Kin Wong, Aristotelis Tsirigos, Cynthia A. Loomis, Argus Athanas, Peter Olson, James G. Christensen, Dean Y. Maeda, John A. Zebala, Carmine Fedele, Yuan Hao, Ting Chen, Kayla Guidry, Han Han, Jayu Jen, Alireza Khodadadi-Jamayran, Shuai Li, Kwan Ho Tang
Figure S1-6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3db55b1f7b0adeca862191754700aa35
https://doi.org/10.1158/2159-8290.22540636.v1
https://doi.org/10.1158/2159-8290.22540636.v1
Autor:
Clint Allen, Paul E. Clavijo, John A. Zebala, Dean Y. Maeda, Jeffrey Schlom, Claudia Palena, Lucas A. Horn, Jay Friedman, Nicole C. Schmitt, Angel P. Huynh, Wojciech K. Mydlarz, Yvette Robbins, Sarah Greene
Supplemental Figure S7. SX-682 treatment does not alter PMN-MDSC suppressive capacity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d32e1729179b2c8191a3483bb36eac6
https://doi.org/10.1158/1078-0432.22478684
https://doi.org/10.1158/1078-0432.22478684
Autor:
Clint Allen, Paul E. Clavijo, John A. Zebala, Dean Y. Maeda, Jeffrey Schlom, Claudia Palena, Lucas A. Horn, Jay Friedman, Nicole C. Schmitt, Angel P. Huynh, Wojciech K. Mydlarz, Yvette Robbins, Sarah Greene
Purpose:Natural killer (NK)-cell–based immunotherapy may overcome obstacles to effective T-cell–based immunotherapy such as the presence of genomic alterations in IFN response genes and antigen presentation machinery. All immunotherapy approaches
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c83b154859a3605e7859ad97fb58723
https://doi.org/10.1158/1078-0432.c.6530021.v1
https://doi.org/10.1158/1078-0432.c.6530021.v1
Autor:
Clint Allen, Paul E. Clavijo, John A. Zebala, Dean Y. Maeda, Jeffrey Schlom, Claudia Palena, Lucas A. Horn, Jay Friedman, Nicole C. Schmitt, Angel P. Huynh, Wojciech K. Mydlarz, Yvette Robbins, Sarah Greene
Methods not essential to the main conclusions but important for critical review of methods used for this work
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee5ecc3ab0347cbce114b16bbcc7a4de
https://doi.org/10.1158/1078-0432.22478678.v1
https://doi.org/10.1158/1078-0432.22478678.v1